Biotechs Will Showcase New Technologies In 2017
BMI View: Small biotechs will generate interest as they display potentially transformative cancer treatments in 2017. While these new technologies are in early stages, they will attract interest from big pharma as they progress through human trials. Gene editing and mRNA vaccines will be closely watched as these highly anticipated treatment modalities gain traction.
The 2017 JP Morgan Healthcare conference set the tone for biotechs for the forthcoming year. Big biotechs, such as Celgene, continue to draw attention, and the company’s 2017 plans were closely scrutinised. Small biotechs also presented, with highly anticipated pipeline updates. Of note , Editas Medicine highlighted its 2017 goals for CRISPR gene editing.